Fintech

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Globenewswire·April 9, 2026 at 11:01 AM

Confirmed, pooled, blinded COVID-19 events in the ongoing Phase 3 DECLARATION study of VYD2311 accumulated to date (~ 50% of study progress) can already...

Original Source

Globenewswire — www.globenewswire.com

Related in Fintech

Treasury Shares Cybersecurity Intel with Crypto Firms
PYMNTS
New Stablecoin Rules Affect Banks and FinTechs
PYMNTS
HOA fees strain household budgets
PYMNTS
Anthropic launches AI agents product
PYMNTS

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Treasury Shares Cybersecurity Intel with Crypto Firms

New Stablecoin Rules Affect Banks and FinTechs

HOA fees strain household budgets

Anthropic launches AI agents product